The country’s drug regulator, the Drug Control General of India (DCGI), on Sunday approved the use of two vaccines in the country amid the corona epidemic.
The country’s drug regulator, the Drug Control General of India (DCGI), on Sunday approved the use of two vaccines in the country amid the corona epidemic. The two vaccines approved by the DCGI for limited emergency use include Kovishield, developed by Oxford University and AstraZeneca in collaboration with the Civil Institute of India, and a full-fledged Kovicin developed by the indigenous pharmaceutical company Bharat Biotech. Don’t blame, we’re a lot of vaccine manufacturers. ” “It’s wrong to say we’re not transparent about the data,” he said. But there is nothing secret in this. On Monday, India rejected biotech criticism that the vaccine was approved despite a lack of efficacy data.
He described Kovacin as one of the safest coron vaccines in the world. Dr. Krishna Ila said, we have done more than 16 clinical trials worldwide. For conducting such a large number of clinical trials we are the largest organization in the developing country It is noteworthy that India Biotech also tested the vaccine on children aged 12-18 years in the second phase. Based on this, DCGI has approved limited use of the vaccine in an emergency in clinical trial mode and has included children 12 years of age or older. However, children were not included in the government’s priority to vaccinate 300 million people.
India Biotech Kovasin can also be applied for children